tyrphostin ag 1024 has been researched along with Cholangiocarcinoma in 1 studies
tyrphostin AG 1024: modulates radiosensitivity in human breast cancer cells; also an IGF1 receptor inhibitor
Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib treatment dose-dependently blocked growth-factor-induced activation of the MAPKP and inhibited the proliferation of EGI-1 and TFK-1 CC cells in a time- and dose-dependent manner." | 5.34 | Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. ( Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007) |
| "Sorafenib treatment dose-dependently blocked growth-factor-induced activation of the MAPKP and inhibited the proliferation of EGI-1 and TFK-1 CC cells in a time- and dose-dependent manner." | 1.34 | Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. ( Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Huether, A | 1 |
| Höpfner, M | 1 |
| Baradari, V | 1 |
| Schuppan, D | 1 |
| Scherübl, H | 1 |
1 other study available for tyrphostin ag 1024 and Cholangiocarcinoma
| Article | Year |
|---|---|
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; | 2007 |